# A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

> **NCT03086239** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 29 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Rovalpituzumab tesirine

## Key facts

- **NCT ID:** NCT03086239
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-28
- **Primary completion:** 2018-01-30
- **Final completion:** 2018-08-20
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086239, "A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03086239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*